Human mesenchymal stromal cells modulate T-cell responses through TNF-α-mediated activation of NF-κψB

被引:83
作者
Dorronsoro, Akaitz [1 ]
Ferrin, Izaskun [1 ]
Manuel Salcedo, Juan [1 ]
Jakobsson, Emma [1 ]
Fernandez-Rueda, Jon [1 ]
Lang, Valerie [2 ]
Sepulveda, Pilar [3 ]
Fechter, Karoline
Pennington, Dan [4 ]
Trigueros, Cesar [1 ]
机构
[1] Fdn Inbiomed, Fdn Stem Cell Res, Mesenchymal & Hematopoiet Stem Cell Lab, San Sebastian 20009, Spain
[2] Fdn Inbiomed, Fdn Stem Cell Res, Ubiquitylat & Canc Mol Biol Lab, San Sebastian 20009, Spain
[3] Fdn Invest Hosp Univ La Fe, Valencia, Spain
[4] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med, London, England
关键词
Immunoregulation; MSC; NF-B; TNF-; STEM-CELLS; LYMPHOCYTE-PROLIFERATION; ADIPOSE-TISSUE; IFN-GAMMA; IN-VITRO; BONE; RECEPTOR; INHIBIT; DEGRADATION; MECHANISMS;
D O I
10.1002/eji.201343668
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
071005 [微生物学]; 100108 [医学免疫学];
摘要
Although mesenchymal stromal cells (MSCs) possess the capacity to modulate immune responses, little is known about the mechanisms that underpin these processes. In this study, we show that immunosupression is mediated by activation of nuclear factor kappa B (NF-B) in human MSCs. This pathway is activated by TNF- that is generated following TCR stimulation of T cells. Inhibition of NF-B through silencing of IB kinase or the TNF- receptor abolishes the immunosuppressive capacity of MSCs. Our data also indicate that MSC-associated NF-B activation primarily leads to inhibition of T-cell proliferation with little effect on expression of the activation markers CD69 and CD25. Thus, our data support the hypothesis that the TNF-/NF-B signalling pathway is required for the initial priming of immunosuppressive function in human MSCs. Interestingly, drugs that interfere with NF-B activation significantly antagonise the immunoregulatory effect of MSCs, which could have important implications for immunosuppression regimens in the clinic.
引用
收藏
页码:480 / 488
页数:9
相关论文
共 40 条
[1]
Glucocorticoid-regulated transcription factors [J].
Adcock, IM .
PULMONARY PHARMACOLOGY & THERAPEUTICS, 2001, 14 (03) :211-219
[2]
Human mesenchymal stem cells modulate allogeneic immune cell responses [J].
Aggarwal, S ;
Pittenger, MF .
BLOOD, 2005, 105 (04) :1815-1822
[3]
The NF-kappa B and I kappa B proteins: New discoveries and insights [J].
Baldwin, AS .
ANNUAL REVIEW OF IMMUNOLOGY, 1996, 14 :649-683
[4]
Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo [J].
Bartholomew, A ;
Sturgeon, C ;
Siatskas, M ;
Ferrer, K ;
McIntosh, K ;
Patil, S ;
Hardy, W ;
Devine, S ;
Ucker, D ;
Deans, R ;
Moseley, A ;
Hoffman, R .
EXPERIMENTAL HEMATOLOGY, 2002, 30 (01) :42-48
[5]
Active roles for inhibitory κB kinases α and β in nuclear factor-κB-mediated chemoresistance to doxorubicin [J].
Bednarski, Brian K. ;
Ding, Xiaoyu ;
Coombe, Kavita ;
Baldwin, Albert S. ;
Kim, Hong J. .
MOLECULAR CANCER THERAPEUTICS, 2008, 7 (07) :1827-1835
[6]
Human Mesenchymal Stem Cells and Immunosuppressive Drug Interactions in Allogeneic Responses: An In Vitro Study Using Human Cells [J].
Buron, F. ;
Perrin, H. ;
Malcus, C. ;
Hequet, O. ;
Thaunat, O. ;
Kholopp-Sarda, M. -N. ;
Moulin, F. T. ;
Morelon, E. .
TRANSPLANTATION PROCEEDINGS, 2009, 41 (08) :3347-3352
[7]
ERK2 protein regulates the proliferation of human mesenchymal stem cells without affecting their mobilization and differentiation potential [J].
Carcamo-Orive, Ivan ;
Tejados, Naiara ;
Delgado, Jesus ;
Gaztelumendi, Ainhoa ;
Otaegui, David ;
Lang, Valerie ;
Trigueros, Cesar .
EXPERIMENTAL CELL RESEARCH, 2008, 314 (08) :1777-1788
[8]
Regulation of Human Bone Marrow Stromal Cell Proliferation and Differentiation Capacity by Glucocorticoid Receptor and AP-1 Crosstalk [J].
Carcamo-Orive, Ivan ;
Gaztelumendi, Ainhoa ;
Delgado, Jesus ;
Tejados, Naiara ;
Dorronsoro, Akaitz ;
Fernandez-Rueda, Jon ;
Pennington, Daniel J. ;
Trigueros, Cesar .
JOURNAL OF BONE AND MINERAL RESEARCH, 2010, 25 (10) :2115-2125
[9]
Caruso A, 1997, CYTOMETRY, V27, P71, DOI 10.1002/(SICI)1097-0320(19970101)27:1<71::AID-CYTO9>3.0.CO
[10]
2-O